hydroxychloroquine has been researched along with epidermal growth factor in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bolce, R; Chernoff, D; Cruickshank, SE; Forslind, K; Geborek, P; Hambardzumyan, K; Petersson, IF; Saevarsdottir, S; Sasso, EH; van Vollenhoven, RF | 1 |
| Bolce, RJ; Ernestam, S; Forslind, K; Hambardzumyan, K; Petersson, IF; Saevarsdottir, S; van Vollenhoven, RF; Wallman, JK | 1 |
1 trial(s) available for hydroxychloroquine and epidermal growth factor
| Article | Year |
|---|---|
Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.
Topics: Adipokines; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; C-Reactive Protein; Chitinase-3-Like Protein 1; Disease Progression; Drug Therapy, Combination; Epidermal Growth Factor; Female; Foot Joints; Hand Joints; Humans; Hydroxychloroquine; Infliximab; Interleukin-6; Lectins; Leptin; Logistic Models; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Methotrexate; Multivariate Analysis; Prognosis; Radiography; Receptors, Tumor Necrosis Factor, Type I; Resistin; Serum Amyloid A Protein; Severity of Illness Index; Sulfasalazine; Treatment Outcome; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2015 |
1 other study(ies) available for hydroxychloroquine and epidermal growth factor
| Article | Year |
|---|---|
A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Blood Sedimentation; C-Reactive Protein; Chitinase-3-Like Protein 1; Decision Support Techniques; Drug Therapy, Combination; Epidermal Growth Factor; Female; Humans; Hydroxychloroquine; Infliximab; Interleukin-6; Leptin; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Methotrexate; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor, Type I; Resistin; Serum Amyloid A Protein; Severity of Illness Index; Sulfasalazine; Treatment Failure; Treatment Outcome; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2017 |